Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...
One of the greatest challenges facing cancer researchers is to understand why some patients don’t respond to treatments. In some cases, tumors exhibit what is known as multidrug resistance (MDR), ...
Researchers are seeking ways to overcome one of the greatest challenges of cancer—understanding why some patients do not respond to treatments. Some tumors exhibit multidrug resistance (MDR), which ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, presented new data on Friday ...
18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography evaluation to predict postoperative outcomes for patient with luminal-type breast cancer. This is an ASCO Meeting Abstract ...
Scientists in Spain have uncovered a mechanism behind why some cancer patients don’t respond well to treatments – and more importantly, found a “weak spot” that could be targeted by existing drugs.
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results